Author: Cho, Sung-Yeon; Lee, Hyeon-Jeong; Lee, Dong-Gun
Title: Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea Document date: 2018_2_27
ID: t9tysvr8_2
Snippet: Until the 1970s, HSCTs were simply classified as au- tologous or allogeneic according to their donor status, and survival rates were very low. Since the introduction of the human leukocyte antigen (HLA) concept, the incidence of graft failure and/or graft-versus-host disease (GVHD) has decreased. In recent years, allogeneic HSCT has involved various sources of hematopoietic stem cells (bone marrow, peripheral stem cell, cord blood, and mesenchyma.....
Document: Until the 1970s, HSCTs were simply classified as au- tologous or allogeneic according to their donor status, and survival rates were very low. Since the introduction of the human leukocyte antigen (HLA) concept, the incidence of graft failure and/or graft-versus-host disease (GVHD) has decreased. In recent years, allogeneic HSCT has involved various sources of hematopoietic stem cells (bone marrow, peripheral stem cell, cord blood, and mesenchymal cells), donors (sibling, unrelated, haploidentical), and conditioning regimens (standard [myeloablative], reduced intensity). Supportive therapies such as transfusion, colony stimulating factors, and antimicrobial agents have also been developed. Although various early diagnosis and therapeutic techniques have been developed to improve transplant performance, infectious diseases still affect the prognosis of HSCT recipients [2] [3] [4] .
Search related documents:
Co phrase search for related documents- hematopoietic stem cell source and host versus graft disease: 1, 2
- hematopoietic stem cell source and hsct recipient: 1
- hematopoietic stem cell source and stem cell: 1, 2
- host versus graft and hsct recipient: 1, 2
- host versus graft and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8
- host versus graft and mesenchymal cell: 1, 2, 3, 4, 5, 6, 7
- host versus graft and peripheral stem cell: 1, 2, 3, 4, 5, 6, 7
- host versus graft and reduced intensity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- host versus graft and stem cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- host versus graft and survival rate: 1, 2, 3, 4, 5, 6, 7, 8, 9
- host versus graft disease and hsct recipient: 1, 2
- host versus graft disease and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8
- host versus graft disease and mesenchymal cell: 1, 2, 3, 4, 5, 6, 7
- host versus graft disease and peripheral stem cell: 1, 2, 3, 4, 5, 6, 7
- host versus graft disease and reduced intensity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- host versus graft disease and stem cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- host versus graft disease and survival rate: 1, 2, 3, 4, 5, 6, 7, 8, 9
- hsct recipient and peripheral stem cell: 1
- hsct recipient and stem cell: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date